Relaxate 10mg Tablet is a tricyclic antidepressant. Different doses of this medicine help in treating and preventing different problems such as depression, neuropathic pain, and migraine.
Rate ₹16.07 (Excluding GST)add_shopping_cart Buy Now favorite_borderAdd to Wishlist comment Give a Feedback * In Stock
Relaxate 10mg Tablet is normally taken before bedtime because it can make you feel sleepy. It can be taken with or without food. The dose and how often you need to take it will be decided by your doctor so that you get the right amount to control your symptoms. The initial dose should be increased with great caution under close supervision. This medicine may not work straight away and it could be several weeks before you get the full effects.This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, help you sleep better, and increase your energy level. This medication belongs to a class of medications called tricyclic antidepressants. It works by affecting the balance of certain natural chemicals (neurotransmitters such as serotonin) in the brain.To reduce your risk of side effects, doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully. This medication may not work right away. You may see some benefit within a week. However, it may take up to 4 weeks before you feel the full effect.
Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerability. Treatment is symptomatic and should therefore be continued for an appropriate length of time. In many patients, therapy may be needed for several years. Regular reassessment is recommended to confirm that continuation of the treatment remains appropriate for the patient.
Treatment must be continued for an appropriate length of time. Regular reassessment is recommended to confirm that continuation of the treatment remains appropriate for the patient, prophylactic treatment of chronic tension type headache and prophylactic treatment of migraine in adults.
Special warnings and precautions for use
Cardiac arrhythmias and severe hypotension are likely to occur with high dosage. They may also occur in patients with pre-existing heart disease taking normal dosage.
QT interval prolongation
Cases of QT interval prolongation and arrhythmia have been reported during the post-marketing period. Caution is advised in patients with significant bradycardia, in patients with uncompensated heart failure,or in patients concurrently taking QT-prolonging drugs. Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) are known to be conditions increasing the proarrythmic risk.
Anaesthetics given during tri/tetracyclic antidepressant therapy may increase the risk of arrhythmias and hypotension. If possible, discontinue this medicinal product several days before surgery; if emergency surgery is unavoidable, the anaesthetist should be informed that the patient is being so treated.
Great care is necessary if amitriptyline is administered to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop.
Elderly patients are particularly susceptible to orthostatic hypotension.
This medical product should be used with caution in patients with convulsive disorders, urinary retention, prostatic hypertrophy, hyperthyroidism, paranoid symptomatology and advanced hepatic or cardiovascular disease, pylorus stenosis and paralytic ileus.
In patients with the rare condition of shallow anterior chamber and narrow chamber angle, attacks of acute glaucoma due to dilation of the pupil may be provoked.
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo- controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
In manic-depressives, a shift towards the manic phase may occur; should the patient enter a manic phase amitriptyline should be discontinued.
As described for other psychotropics, amitriptyline may modify insulin and glucose responses calling for adjustment of the antidiabetic therapy in diabetic patients; in addition the depressive illness itself may affect patients' glucose balance.
Hyperpyrexia has been reported with tricyclic antidepressants when administered with anticholinergic or with neuroleptic medications, especially in hot weather.
After prolonged administration, abrupt cessation of therapy may produce withdrawal symptoms such as headache, malaise, insomnia and irritability.
Amitriptyline should be used with caution in patients receiving SSRIs (see sections 4.2 and 4.5).
An ECG should be performed prior to initiating therapy with amitriptyline to exclude long QT syndrome. Amitriptyline for enuresis should not be combined with an anticholinergic drug. Suicidal thoughts and behaviours may also develop during early treatment with antidepressants for disorders other than depression; the same precautions observed when treating patients with depression should therefore be followed when treating patients with enuresis.
Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are not available (see section 4.2).
This product contains liquid maltitol. Patients with rare hereditary problems of fructose should not take this medicine. Daily quantities of 10g or more may have a mild laxative effect. Calorific value 2.3 kcal/g maltitol.
Methyl and propyl hydroxybenzoates are contained in this product which may cause allergic reactions (possibly delayed).
This product contains small amounts of ethanol (alcohol), less than 100mg per dose.
This product contains 100 mg propylene glycol in each 5ml dose which is equivalent to 20mg/ml.
Orosys Pharma is a leading non-government pharmaceutical company in India. It started its journey from January 2019. Within this short span of time it already marked its position as a trusted company for patient-oriented services.About Us
Orosys Pharma always hunting for innovating new health solutions.
We always focus to provide best quality products.
We always believe in Go Green, always there to Care.
We always care about our employees as they are asset of us.